[go: up one dir, main page]

AR051965A1 - Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida - Google Patents

Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida

Info

Publication number
AR051965A1
AR051965A1 ARP050104879A ARP050104879A AR051965A1 AR 051965 A1 AR051965 A1 AR 051965A1 AR P050104879 A ARP050104879 A AR P050104879A AR P050104879 A ARP050104879 A AR P050104879A AR 051965 A1 AR051965 A1 AR 051965A1
Authority
AR
Argentina
Prior art keywords
oxoetil
metoxipiridin
trifluormetil
ciclohexil
benzamida
Prior art date
Application number
ARP050104879A
Other languages
English (en)
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AR051965A1 publication Critical patent/AR051965A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Reivindicacion 1: Una sal farmacéutica aceptable de un compuesto de la formula (1), caracterizada en que dicha sal es una sal del ácido metanosulfonico, del ácido bis etanosulfonico o del ácido canforico.
ARP050104879A 2004-11-22 2005-11-21 Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida AR051965A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63014604P 2004-11-22 2004-11-22
US69963705P 2005-07-15 2005-07-15

Publications (1)

Publication Number Publication Date
AR051965A1 true AR051965A1 (es) 2007-02-21

Family

ID=36647947

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104879A AR051965A1 (es) 2004-11-22 2005-11-21 Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida

Country Status (10)

Country Link
US (1) US20060111404A1 (es)
EP (1) EP1819694A2 (es)
JP (1) JP2008520722A (es)
AR (1) AR051965A1 (es)
CA (1) CA2587919A1 (es)
PA (1) PA8653301A1 (es)
PE (1) PE20061082A1 (es)
TW (1) TW200633703A (es)
UY (1) UY29219A1 (es)
WO (1) WO2006073592A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20115290B (en) 2002-11-27 2011-09-26 Incyte Corp 3-aminopyrrolidine derivatives as modulators of chemokine receptors
WO2005060665A2 (en) * 2003-12-18 2005-07-07 Incyte Corporation 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
EP1763351B9 (en) * 2004-06-28 2017-05-31 Incyte Holdings Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
US7910108B2 (en) 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
WO2008145681A2 (en) * 2007-05-31 2008-12-04 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
WO2009130915A1 (ja) 2008-04-25 2009-10-29 株式会社日本触媒 ポリアクリル酸（塩）系吸水性樹脂およびその製造方法
EA018997B1 (ru) * 2008-12-10 2013-12-30 Янссен Фармацевтика Нв Антагонисты ccr2 группы 4-азетидинил-1-гетероарилциклогексанола
CN102256963B (zh) 2008-12-19 2014-06-11 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
WO2010090324A1 (ja) 2009-02-06 2010-08-12 株式会社日本触媒 ポリアクリル酸（塩）系吸水性樹脂およびその製造方法
CN102459225B (zh) 2009-04-16 2014-08-20 詹森药业有限公司 Ccr2的4-氮杂环丁烷基-1-杂芳基-环己烷拮抗剂
AU2010236336B2 (en) * 2009-04-17 2015-01-15 Janssen Pharmaceutica Nv 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of CCR2
ES2528625T3 (es) * 2009-04-17 2015-02-11 Janssen Pharmaceutica Nv Antagonistas de 4-azetidinil-1-fenil-ciclohexano de CCR2
KR101151415B1 (ko) * 2009-07-10 2012-06-01 양지화학 주식회사 Ｃｃｒ２ 길항제로서의 피페라지닐에틸 3-아미노피롤리딘 유도체
US9138505B2 (en) 2009-08-27 2015-09-22 Nippon Shokubai Co., Ltd. Polyacrylic acid (salt)-type water absorbent resin and method for producing of same
WO2011040472A1 (ja) 2009-09-29 2011-04-07 株式会社日本触媒 粒子状吸水剤及びその製造方法
PT2513093E (pt) 2009-12-17 2014-10-22 Boehringer Ingelheim Int Novos antagonistas do receptor ccr2 e suas utilizações
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
AU2011268375B2 (en) * 2010-06-17 2015-02-05 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
EP3520978B1 (en) 2013-08-28 2020-11-04 Nippon Shokubai Co., Ltd. Polyacrylic acid (salt)-based water absorbent resin powder
EP3040362B1 (en) 2013-08-28 2018-08-08 Nippon Shokubai Co., Ltd. Gel pulverization device, and related method for manufacturing superabsorbent polymer powder
RS62809B1 (sr) 2015-05-21 2022-02-28 Chemocentryx Inc Modulatori ccr2
AU2016287584B2 (en) 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
US11304952B2 (en) 2017-09-25 2022-04-19 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
EP3737367B1 (en) 2018-01-08 2024-10-02 ChemoCentryx, Inc. Ccr2 antagonists for the treatment of cutaneous t-cell lymphoma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU175454B (hu) * 1977-07-25 1980-08-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh predel'nykh i chastichno predel'nykh n-acil-pirrol-2,5-dionov
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
EE200000294A (et) * 1997-11-18 2001-08-15 Teijin Limited Tsüklilised amiini derivaadid ning meetod kemokiini seondumise sihtraku retseptoriga ja/või kemokiini toime sihtrakule inhibeerimiseks
GB2355263A (en) * 1999-09-30 2001-04-18 Merck & Co Inc Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
US6410566B1 (en) * 2000-05-16 2002-06-25 Teijin Limited Cyclic amine derivatives and their use as drugs
GEP20115290B (en) * 2002-11-27 2011-09-26 Incyte Corp 3-aminopyrrolidine derivatives as modulators of chemokine receptors

Also Published As

Publication number Publication date
WO2006073592A2 (en) 2006-07-13
PE20061082A1 (es) 2006-12-08
UY29219A1 (es) 2006-04-28
JP2008520722A (ja) 2008-06-19
PA8653301A1 (es) 2006-11-09
TW200633703A (en) 2006-10-01
CA2587919A1 (en) 2006-07-13
US20060111404A1 (en) 2006-05-25
EP1819694A2 (en) 2007-08-22
WO2006073592A3 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
AR051965A1 (es) Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida
ES2572980T3 (es) Combinación de inhibidores de la proteasa del VHC con un tensioactivo
EA201000300A1 (ru) Способ синтеза соединений, пригодных для лечения гепатита с
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
AR057467A1 (es) Sales de 4- metil-n-(3-(4-metilimidazol-1-il)-5- trifluorometil- fenil)-3- (4- metil- imidazol-1-il)-5- trifluorometil - fenil)-3-(4- piridin -3- il pirimidin-2- lamino ) - benzamida. metodo de preparacion y composiciones farmaceuticas
AR104566A2 (es) Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo
GT200600496A (es) Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea.
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
CL2013002737A1 (es) Acido 4-((4-((((1r, 2s)-2-fenilciclopropil)amino)metil)piperidin-1-il)metil)benzoico con actividad inhibidora de desmetilasa 1 especifica de lisina (lsd1); composicion farmaceutica que lo comprende, utiles en el tratamiento del cancer.
PE20120517A1 (es) Inhibidores del virus de la hepatitis c
DE602005008611D1 (de) Neuer steroidagonist für fxr
DK1712547T3 (da) Bicycloesterderivat
ATE536349T1 (de) In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
DE60226467D1 (de) Peptidylketone als inhibitoren der dpiv
CY1107141T1 (el) Μεθοδος για την παρασκευη της 1-(2s,3s)-2-βενζυδρυλ-ν-(5-τριτ.-βουτυλ-2-μεθοξυβενζυλ)κινουκλιδιν-3-αμινης
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
AR065798A1 (es) Usos terapeuticos de la 4-[2-(4-metilfenilsulfanil)fenil]piperidina
CO6361988A2 (es) Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)fenil]piperidina.
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
AR113778A2 (es) Composición farmacéutica que comprende una sal de difosfato de n-[6-(cis-2,6-dimetilmorfolin-4-il)piridin-3-il]-2-metil-4’-(trifluormetoxi)[1,1’-bifenil]-3-carboxamida
AR038571A1 (es) Procedimiento para la preparacion de un producto de inhalacion en polvo que contiene una sal del antagonista de cgrp, bibn4096
EA200700756A1 (ru) Пиримидоны
CO5720995A2 (es) Compuesto novedoso
NO20064982L (no) 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav
EA200801507A1 (ru) Оптически активные карбаматы, способ их получения и их применение в качестве фармацевтических промежуточных соединений

Legal Events

Date Code Title Description
FB Suspension of granting procedure